Please login to the form below

Not currently logged in

David Khougazian appointed president of Sanofi Pasteur MSD

He will succeed Dr Jean-Paul Kress atthe Sanofi Pasteur - Merck & Co venture

Sanofi Pasteur MSD David KhougazianSanofi Pasteur MSD has appointed David Khougazian as its new president, a role he will take up on September 1, when he will succeed Dr Jean-Paul Kress at the Sanofi Pasteur - Merck  & Co venture.

Kress, who has led the company since July 2011, will then leave Sanofi Pasteur MSD to join the Sanofi group - which recently announced a major restructuring of its business.

Khougazian moves to the vaccines-focused firm from a position as Sanofi CEO chief of staff, which he held since 2011.

Prior to this he had a number of business operations positions in sales and marketing and as general manager, having joined Rhône-Poulenc (now part of Sanofi) in 1997.

Olivier Charmeil, president and CEO of Sanofi Pasteur, said: “Sanofi Pasteur MSD is a major player in the European vaccines market. David's appointment marks a new phase in our development in Western Europe; a challenging and strategic region for our vaccines activity.

“His knowledge of European markets and external stakeholders will be a strong asset to grow Sanofi Pasteur MSD's position in Europe.”

23rd July 2015

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...